Keywords: teva, profit, down, barr, merger, costs, israeli
Teva profit down 67% on Barr merger costs
Article | 23 February 2009
Israeli generics giant Teva Pharmaceutical Industries' profit for 2008 fell 67%, year-on-year, due to expenses related to the acquisition of Barr Pharmaceuticals.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
